Stocktoria
NextCure, Inc. NXTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-09
NextCure, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $44.9M | $41.5M | $47.9M | $54.2M | $50.2M |
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M | -$70.8M |
| Income tax | $0 | — | — | — | — |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M | -$69.4M |
| EPS (diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 |
| Operating cash flow | -$49.6M | -$40.8M | -$53.0M | -$53.9M | -$57.3M |
| Free cash flow | — | -$41.3M | -$53.8M | -$56.0M | -$59.6M |
| Cash & equivalents | $26.0M | $27.7M | $13.1M | $26.6M | $12.3M |
| Total assets | $50.2M | $80.9M | $128.0M | $184.2M | $242.4M |
| Total liabilities | $15.2M | $15.4M | $13.6M | $16.6M | $9.0M |
| Shareholders' equity | $34.9M | $65.5M | $114.4M | $167.5M | $233.4M |
Source: SEC EDGAR filings · CIK 0001661059 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.